{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:50:31Z","timestamp":1791669031732,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the CAMS Innovation Fund for Medical Sciences","award":["2024-I2M-C&T-B-009"],"award-info":[{"award-number":["2024-I2M-C&T-B-009"]}]},{"name":"the National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-C-028"],"award-info":[{"award-number":["2022-PUMCH-C-028"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-026-04811-4","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:40:25Z","timestamp":1791668425000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Synergistic antitumor effects of 5-fluorouracil and vorinostat in preclinical models of pheochromocytomas and paragangliomas"],"prefix":"10.1007","volume":"91","author":[{"given":"Wenqian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunying","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zewen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1418-1012","authenticated-orcid":false,"given":"Anli","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,10]]},"reference":[{"key":"4811_CR1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1210\/endrev\/bnab019","volume":"43","author":"S N\u00f6lting","year":"2022","unstructured":"S. N\u00f6lting, N. Bechmann, D. Taieb et al. Personalized management of pheochromocytoma and paraganglioma. Endocr. Rev. 43, 199\u2013239 (2022). https:\/\/doi.org\/10.1210\/endrev\/bnab019","journal-title":"Endocr. Rev."},{"key":"4811_CR2","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1210\/jc.2018-01968","volume":"104","author":"S Hescot","year":"2019","unstructured":"S. Hescot, M. Curras-Freixes, T. Deutschbein et al. Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-Prono Study): a european network for the study of adrenal tumors retrospective study. J. Clin. Endocrinol. Metab. 104, 2367\u20132374 (2019). https:\/\/doi.org\/10.1210\/jc.2018-01968","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4811_CR3","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1056\/NEJMoa2504964","volume":"393","author":"C Jimenez","year":"2025","unstructured":"C. Jimenez, M. Andreassen, A. Durand et al. Belzutifan for advanced pheochromocytoma or paraganglioma. N. Engl. J. Med. 393, 2012\u20132022 (2025). https:\/\/doi.org\/10.1056\/NEJMoa2504964","journal-title":"N. Engl. J. Med."},{"key":"4811_CR4","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/s1470-2045(24)00133-5","volume":"25","author":"C Jimenez","year":"2024","unstructured":"C. Jimenez, M.A. Habra, M.T. Campbell et al. Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial. Lancet Oncol. 25, 658\u2013667 (2024). https:\/\/doi.org\/10.1016\/s1470-2045(24)00133-5","journal-title":"Lancet Oncol."},{"key":"4811_CR5","doi-asserted-by":"publisher","first-page":"3702","DOI":"10.3390\/cancers17223702","volume":"17","author":"I Ghosh","year":"2025","unstructured":"I. Ghosh, O. Benson, J.H. Hernandez-Felix et al. Update on systemic therapies for metastatic\/unresectable pheochromocytomas and paragangliomas and future directions. Cancers 17, 3702 (2025). https:\/\/doi.org\/10.3390\/cancers17223702","journal-title":"Cancers"},{"key":"4811_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01047-x","volume":"21","author":"A Mafi","year":"2023","unstructured":"A. Mafi, M. Rezaee, N. Hedayati et al. Melatonin and 5-fluorouracil combination chemotherapy: opportunities and efficacy in cancer therapy. Cell Commun. Signal. 21, 33 (2023). https:\/\/doi.org\/10.1186\/s12964-023-01047-x","journal-title":"Cell Commun. Signal."},{"key":"4811_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36769-6","volume":"14","author":"B Calsina","year":"2023","unstructured":"B. Calsina, E. Pi\u00f1eiro-Y\u00e1\u00f1ez, \u00c1.M. Mart\u00ednez-Montes et al. Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma. Nat. Commun. 14, 1122 (2023). https:\/\/doi.org\/10.1038\/s41467-023-36769-6","journal-title":"Nat. Commun."},{"key":"4811_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","volume":"31","author":"L Fishbein","year":"2017","unstructured":"L. Fishbein, I. Leshchiner, V. Walter et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell 31, 181\u2013193 (2017). https:\/\/doi.org\/10.1016\/j.ccell.2017.01.001","journal-title":"Cancer Cell"},{"key":"4811_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/jso.2930270207","volume":"27","author":"RM Bukowski","year":"1984","unstructured":"R.M. Bukowski, D.G. Vidt, Chemotherapy trials in malignant pheochromocytoma: report of two patients and review of the literature. J. Surg. Oncol. 27, 89\u201392 (1984). https:\/\/doi.org\/10.1002\/jso.2930270207","journal-title":"J. Surg. Oncol."},{"key":"4811_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/bf00685513","volume":"28","author":"V Srimuninnimit","year":"1991","unstructured":"V. Srimuninnimit, G.L. Wampler, Case report of metastatic familial pheochromocytoma treated with cisplatin and 5-fluorouracil. Cancer Chemother. Pharmacol. 28, 217\u2013219 (1991). https:\/\/doi.org\/10.1007\/bf00685513","journal-title":"Cancer Chemother. Pharmacol."},{"key":"4811_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119504","volume":"277","author":"MJ Ramaiah","year":"2021","unstructured":"M.J. Ramaiah, A.D. Tangutur, R.R. Manyam, Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy. Life Sci. 277, 119504 (2021). https:\/\/doi.org\/10.1016\/j.lfs.2021.119504","journal-title":"Life Sci."},{"key":"4811_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-024-01551-8","volume":"17","author":"MQ Shi","year":"2024","unstructured":"M.Q. Shi, Y. Xu, X. Fu et al. Advances in targeting histone deacetylase for treatment of solid tumors. J. Hematol. Oncol. 17, 37 (2024). https:\/\/doi.org\/10.1186\/s13045-024-01551-8","journal-title":"J. Hematol. Oncol."},{"key":"4811_CR13","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1158\/1535-7163.Mct-06-0419","volume":"5","author":"JH Lee","year":"2006","unstructured":"J.H. Lee, J.H. Park, Y. Jung et al. Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells. Mol. Cancer Ther. 5, 3085\u20133095 (2006). https:\/\/doi.org\/10.1158\/1535-7163.Mct-06-0419","journal-title":"Mol. Cancer Ther."},{"key":"4811_CR14","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/ijc.24403","volume":"125","author":"W Fazzone","year":"2009","unstructured":"W. Fazzone, P.M. Wilson, M.J. Labonte et al. Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells. Int. J. Cancer 125, 463\u2013473 (2009). https:\/\/doi.org\/10.1002\/ijc.24403","journal-title":"Int. J. Cancer"},{"key":"4811_CR15","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1111\/j.1349-7006.2010.01559.x","volume":"101","author":"R Noro","year":"2010","unstructured":"R. Noro, A. Miyanaga, Y. Minegishi et al. Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU\/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1\/cip1) expression. Cancer Sci. 101, 1424\u20131430 (2010). https:\/\/doi.org\/10.1111\/j.1349-7006.2010.01559.x","journal-title":"Cancer Sci."},{"key":"4811_CR16","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.surg.2008.08.027","volume":"144","author":"JT Adler","year":"2008","unstructured":"J.T. Adler, D.G. Hottinger, M. Kunnimalaiyaan, H. Chen, Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells. Surgery 144, 956\u2013961 (2008). https:\/\/doi.org\/10.1016\/j.surg.2008.08.027","journal-title":"Surgery"},{"key":"4811_CR17","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","volume":"12","author":"BS Mann","year":"2007","unstructured":"B.S. Mann, J.R. Johnson, M.H. Cohen et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12, 1247\u20131252 (2007). https:\/\/doi.org\/10.1634\/theoncologist.12-10-1247","journal-title":"Oncologist"},{"key":"4811_CR18","doi-asserted-by":"publisher","first-page":"26729","DOI":"10.1074\/jbc.C500186200","volume":"280","author":"P Bali","year":"2005","unstructured":"P. Bali, M. Pranpat, J. Bradner et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 280, 26729\u201326734 (2005). https:\/\/doi.org\/10.1074\/jbc.C500186200","journal-title":"J. Biol. Chem."},{"key":"4811_CR19","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41375-019-0493-x","volume":"34","author":"M Ho","year":"2020","unstructured":"M. Ho, T. Chen, J. Liu et al. Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling. Leukemia 34, 196\u2013209 (2020). https:\/\/doi.org\/10.1038\/s41375-019-0493-x","journal-title":"Leukemia"},{"key":"4811_CR20","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"T.C. Chou, Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621\u2013681 (2006). https:\/\/doi.org\/10.1124\/pr.58.3.10","journal-title":"Pharmacol. Rev."},{"key":"4811_CR21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1530\/erc-13-0494","volume":"21","author":"N Kimura","year":"2014","unstructured":"N. Kimura, R. Takayanagi, N. Takizawa et al. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr. Relat. Cancer 21, 405\u2013414 (2014). https:\/\/doi.org\/10.1530\/erc-13-0494","journal-title":"Endocr. Relat. Cancer"},{"key":"4811_CR22","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1530\/erc-21-0355","volume":"29","author":"K Wang","year":"2022","unstructured":"K. Wang, I. Sch\u00fctze, S. Gulde et al. Personalized drug testing in human pheochromocytoma\/paraganglioma primary cultures. Endocr. Relat. Cancer 29, 285\u2013306 (2022). https:\/\/doi.org\/10.1530\/erc-21-0355","journal-title":"Endocr. Relat. Cancer"},{"key":"4811_CR23","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/cbin.11493","volume":"45","author":"N Wang","year":"2021","unstructured":"N. Wang, L. Yang, J. Dai et al. 5-FU inhibits migration and invasion of CRC cells through PI3K\/AKT pathway regulated by MARCH1. Cell Biol. Int. 45, 368\u2013381 (2021). https:\/\/doi.org\/10.1002\/cbin.11493","journal-title":"Cell Biol. Int."},{"key":"4811_CR24","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1111\/cas.14532","volume":"111","author":"S Blondy","year":"2020","unstructured":"S. Blondy, V. David, M. Verdier et al. 5-Fluorouracil resistance mechanisms in colorectal cancer: from classical pathways to promising processes. Cancer Sci. 111, 3142\u20133154 (2020). https:\/\/doi.org\/10.1111\/cas.14532","journal-title":"Cancer Sci."},{"key":"4811_CR25","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1093\/annonc\/mdx411","volume":"28","author":"LM Henricks","year":"2017","unstructured":"L.M. Henricks, F.L. Opdam, J.H. Beijnen et al. DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update. Ann. Oncol. 28, 2915\u20132922 (2017). https:\/\/doi.org\/10.1093\/annonc\/mdx411","journal-title":"Ann. Oncol."},{"key":"4811_CR26","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1677\/erc.1.01249","volume":"13","author":"V Baradari","year":"2006","unstructured":"V. Baradari, A. Huether, M. H\u00f6pfner et al. Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells. Endocr. Relat. Cancer 13, 1237\u20131250 (2006). https:\/\/doi.org\/10.1677\/erc.1.01249","journal-title":"Endocr. Relat. Cancer"},{"key":"4811_CR27","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.3390\/ijms19103128","volume":"19","author":"J Wanek","year":"2018","unstructured":"J. Wanek, M. Gaisberger, M. Beyreis et al. Pharmacological inhibition of class IIA HDACs by LMK-235 in pancreatic neuroendocrine tumor cells. Int. J. Mol. Sci. 19, 3128 (2018). https:\/\/doi.org\/10.3390\/ijms19103128","journal-title":"Int. J. Mol. Sci."},{"key":"4811_CR28","first-page":"178","volume":"1","author":"MA Cayo","year":"2009","unstructured":"M.A. Cayo, A.K. Cayo, S.M. Jarjour, H. Chen, Sodium butyrate activates Notch1 signaling, reduces tumor markers, and induces cell cycle arrest and apoptosis in pheochromocytoma. Am. J. Transl. Res. 1, 178\u2013183 (2009)","journal-title":"Am. J. Transl. Res."},{"key":"4811_CR29","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1677\/erc-10-0090","volume":"18","author":"L Martiniova","year":"2011","unstructured":"L. Martiniova, S.M. Perera, F.M. Brouwers et al. Increased uptake of [\u00b9\u00b2\u00b3I]meta-iodobenzylguanidine, [\u00b9\u2078F]fluorodopamine, and [\u00b3H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors. Endocr. Relat. Cancer 18, 143\u2013157 (2011). https:\/\/doi.org\/10.1677\/erc-10-0090","journal-title":"Endocr. Relat. Cancer"},{"key":"4811_CR30","doi-asserted-by":"publisher","first-page":"278","DOI":"10.7150\/thno.77918","volume":"13","author":"M Ullrich","year":"2023","unstructured":"M. Ullrich, S. Richter, J. Liers et al. Epigenetic drugs in somatostatin type 2 receptor radionuclide theranostics and radiation transcriptomics in mouse pheochromocytoma models. Theranostics 13, 278\u2013294 (2023). https:\/\/doi.org\/10.7150\/thno.77918","journal-title":"Theranostics"},{"key":"4811_CR31","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1634\/theoncologist.2016-0060","volume":"21","author":"N Jin","year":"2016","unstructured":"N. Jin, S.J. Lubner, D.L. Mulkerin et al. A phase II trial of a histone deacetylase inhibitor panobinostat in patients with low-grade neuroendocrine tumors. Oncologist 21, 785\u2013786 (2016). https:\/\/doi.org\/10.1634\/theoncologist.2016-0060","journal-title":"Oncologist"},{"key":"4811_CR32","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/oncolo\/oyae118","volume":"29","author":"JK Jamison","year":"2024","unstructured":"J.K. Jamison, M. Zhou, E.P. Gelmann et al. Entinostat in patients with relapsed or refractory abdominal neuroendocrine tumors. Oncologist 29, 817\u2013e1213 (2024). https:\/\/doi.org\/10.1093\/oncolo\/oyae118","journal-title":"Oncologist"},{"key":"4811_CR33","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/j.juro.2014.11.091","volume":"193","author":"MJ Kim","year":"2015","unstructured":"M.J. Kim, J.S. Lee, S.E. Park et al. Combination treatment of renal cell carcinoma with belinostat and 5-fluorouracil: a role for oxidative stress induced DNA damage and HSP90 regulated thymidine synthase. J. Urol. 193, 1660\u20131668 (2015). https:\/\/doi.org\/10.1016\/j.juro.2014.11.091","journal-title":"J. Urol."},{"key":"4811_CR34","doi-asserted-by":"publisher","first-page":"9347","DOI":"10.1007\/s13277-015-3497-9","volume":"36","author":"B Liao","year":"2015","unstructured":"B. Liao, H. Liang, J. Chen et al. Suberoylanilide hydroxamic acid enhances chemosensitivity to 5-fluorouracil in hepatocellular carcinoma via inhibition of thymidylate synthase. Tumour Biol. 36, 9347\u20139356 (2015). https:\/\/doi.org\/10.1007\/s13277-015-3497-9","journal-title":"Tumour Biol."},{"key":"4811_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2023.116786","volume":"482","author":"Y Wu","year":"2024","unstructured":"Y. Wu, C.S. Li, R.Y. Meng et al. Regulation of Hippo-YAP\/CTGF signaling by combining an HDAC inhibitor and 5-fluorouracil in gastric cancer cells. Toxicol. Appl. Pharmacol. 482, 116786 (2024). https:\/\/doi.org\/10.1016\/j.taap.2023.116786","journal-title":"Toxicol. Appl. Pharmacol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04811-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04811-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04811-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:40:26Z","timestamp":1791668426000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04811-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,10]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4811"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04811-4","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,10]]},"assertion":[{"value":"31 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the institutional ethics committee of Peking Union Medical College Hospital, and written informed consent was obtained from each patient. All animal procedures, including tumor transplantation, tumor volume monitoring and euthanasia, were approved by the Institutional Animal Care and Use Committee at Peking Union Medical College Hospital.","order":1,"name":"Ethics","label":"Ethics statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"345"}}